Study Stopped
The development program has been terminated
GALLANT 22 Tesaglitazar vs. Placebo
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes
2 other identifiers
interventional
475
13 countries
100
Brief Summary
This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 6-week single-blind placebo run-in period, followed by 24-week treatment period and a 3-week follow-up period. The study design of GALLANT 2 is identical to GALLANT 22; the blinded study data from GALLANT 2 will be transferred to the GALLANT 22 database and will be analyzed together with the data from GALLANT 22 clinical study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 type-2-diabetes
Started Apr 2005
100 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 10, 2005
CompletedFirst Posted
Study publicly available on registry
November 15, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedMarch 17, 2008
March 1, 2008
November 10, 2005
March 14, 2008
Conditions
Outcome Measures
Primary Outcomes (1)
Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
Secondary Outcomes (14)
Changes in the following variables from baseline to the end of the randomized treatment period:
Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c
C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio
Fasting plasma glucose (FPG), homeostasis assessment model, insulin, proinsulin, C-peptide
Tumor necrosis factor-alpha, intracellular adhesion molecule-1
- +9 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Provision of a written informed consent
- Men or women who are \>=18 years of age
- Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
- Diagnosed with type 2 diabetes
- Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
- Drug-naïve (ie, no use of antidiabetic drug\[s\], for at least 24 weeks prior to visit 1).
You may not qualify if:
- Type 1 diabetes
- New York Heart Association heart failure Class III or IV
- Treatment with chronic insulin
- History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
- History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
- Creatinine levels above twice the normal range
- Creatine kinase above 3 times the upper limit of normal
- Received any investigational product in other clinical studies within 12 weeks
- Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (101)
Research Site
Adelaide, Australia
Research Site
Cairns, Australia
Research Site
Gosford, Australia
Research Site
Keswick, Australia
Research Site
Kippa-Ring, Australia
Research Site
Melbourne, Australia
Research Site
Miranda, Australia
Research Site
Nowra, Australia
Research Site
Wollongong, Australia
Research Site
Brno, Czechia
Research Site
Hodonín, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Příbram, Czechia
Research Site
Semily, Czechia
Research Site
Tábor, Czechia
Research Site
Ústí nad Labem, Czechia
Research Site
Paide, Estonia
Research Site
Pärnu, Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Viljandi, Estonia
Research Site
Angers, France
Research Site
Briollay, France
Research Site
Poitiers, France
Research Site
Saint-Benoît, France
Research Site
Saint-Ouen, France
Research Site
Toulouse, France
Research Site
Trélazé, France
Research Site
Athens, Greece
Research Site
Piraeus, Greece
Research Site
Balatonfüred, Hungary
Research Site
Budapest, Hungary
Research Site
Kaposvár, Hungary
Research Site
Kecskemét, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Daugavpils, Latvia
Research Site
Jēkabpils, Latvia
Research Site
Madona, Latvia
Research Site
Riga, Latvia
Research Site
Sigulda, Latvia
Research Site
Talsi, Latvia
Research Site
Valmiera, Latvia
Research Site
Kaunas, Lithuania
Research Site
Klaipėda, Lithuania
Research Site
Panevezys, Lithuania
Research Site
Vilnius, Lithuania
Research Site
Aursmoen, Norway
Research Site
Bergen, Norway
Research Site
Enebakk, Norway
Research Site
Fredrikstad, Norway
Research Site
Haugesund, Norway
Research Site
Hønefoss, Norway
Research Site
Inderøy, Norway
Research Site
Larvik, Norway
Research Site
Lierskogen, Norway
Research Site
Oslo, Norway
Research Site
Rolvsøy, Norway
Research Site
Cebu City, Philippines
Research Site
Pasig, Philippines
Research Site
Quezon City, Philippines
Research Site
Katowice, Ochojec, Poland
Research Site
Bialystok, Poland
Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Olsztyn, Poland
Research Site
Poznan, Poland
Research Site
Radom, Poland
Research Site
Rzeszów, Poland
Research Site
Sopot, Poland
Research Site
Szczecin, Poland
Research Site
Toruñ, Poland
Research Site
Tychy, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland
Research Site
Zabrze, Poland
Research Site
Zielona Góra, Poland
Research Site
Belgrade, Serbia and Montenegro
Research Site
Dolný Kubín, Slovakia
Research Site
Levice, Slovakia
Research Site
Lučenec, Slovakia
Research Site
Ľubochňa, Slovakia
Research Site
Nové Zámky, Slovakia
Research Site
Považská Bystrica, Slovakia
Research Site
Šahy, Slovakia
Research Site
Trenčín, Slovakia
Research Site
Veľký Meder, Slovakia
Research Site
Žilina, Slovakia
Research Site
Åmål, Sweden
Research Site
Borås, Sweden
Research Site
Gothenburg, Sweden
Research Site
Mölndal, Sweden
Research Site
Partille, Sweden
Research Site
Skene, Sweden
Research Site
Stenungsund, Sweden
Research Site
Uddevalla, Sweden
Research Site
Vänersborg, Sweden
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca Galida Medical Science Director, MD
AstraZeneca
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 10, 2005
First Posted
November 15, 2005
Study Start
April 1, 2005
Study Completion
December 1, 2006
Last Updated
March 17, 2008
Record last verified: 2008-03